Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Supportive and palliative care

2693 - Anticipative approach to improve safety: An innovative Daily Hospital Organisation


09 Sep 2017


Supportive and palliative care


Florian Scotté


Annals of Oncology (2017) 28 (suppl_5): v543-v567. 10.1093/annonc/mdx388


F. Scotté1, R.T. Elaidi2, H. Haboudagga3, C. Thibault2, J. Stevens4, B. Bonan5, S. Oudard2

Author affiliations

  • 1 Medical Oncology And Supportive Care Unit, Foch Hospital, 92 - Suresnes/FR
  • 2 Medical Oncology, Georges Pompidou European Hospital, 75015 - Paris/FR
  • 3 Pharmacy, Georges Pompidou European Hospital, 75015 - Paris/FR
  • 4 Medical Oncology, Direct Medica, 92 - Boulogne/FR
  • 5 Pharmacy Department, Foch Hospital, 92 - Suresnes/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2693


The PROCHE [Programme for optimisation of the chemotherapy network] initiative is an innovative oncology-monitoring program designed to reduce patient waiting time and chemotherapy wastage, ultimately improving patient care. A nurse calls patients 48 hours before anticancer treatment at the daily hospital to anticipate chemotherapy preparation.


Primary objective was to evaluate the incidence of different symptoms reported by grade (NCI-CTC AE: from 0 to 4) prospectively collected from 2008 to 2016. Secondary objective compared the 2009-2016 patients to the control cohort (2008 period) quantified using Mantel-Haenszel khi2 and exact p-values.


From January 2009 to December 2016, 3012 patients were enrolled in the program, representing 36 803 questionnaires completed over the whole period. Main adverse events (AE) were collected and compared to the control cohorts (2008, n = 513), resulting in a significant decrease in majority of topics. Global incidence comparison is presented in table 1, with the p-value according to khi2 test. Details of severity levels scores using NCI CTC-AE V4.0, will be reported at ESMO meeting. For some of the toxicities, severe or life threatening toxicities (grades 3-4) were higher in the PROCHE cohort, while global incidence decreased.rnTable:


Adverse Event2008 (%)2009-2016 (%)p-value


The PROCHE initiative resulted in adverse events decrease and improved patient quality of care and improved hospital as well as pharmacy efficacy.

Clinical trial identification

Legal entity responsible for the study

Florian Scotté




F. Scotté: Roche, Vifor, MSD, Teva, Norgine, Prostrakan, Leo pharma, Janssen, Hospira, Boehringer, Sanofi, Amgen, Pierre Fabre Oncologie, Tesaro. C. Thibault: Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.